| Literature DB >> 30408305 |
Kjetil Hansen1, Andy M Lau1, Kevin Giles2, James M McDonnell3, Weston B Struwe4, Brian J Sutton3, Argyris Politis1.
Abstract
Immunoglobulins are biomolecules involved in defence against foreign substances. Flexibility is key to their functional properties in relation to antigen binding and receptor interactions. We have developed an integrative strategy combining ion mobility mass spectrometry (IM-MS) with molecular modelling to study the conformational dynamics of human IgG antibodies. Predictive models of all four human IgG subclasses were assembled and their dynamics sampled in the transition from extended to collapsed state during IM-MS. Our data imply that this collapse of IgG antibodies is related to their intrinsic structural features, including Fab arm flexibility, collapse towards the Fc region, and the length of their hinge regions. The workflow presented here provides an accurate structural representation in good agreement with the observed collision cross section for these flexible IgG molecules. These results have implications for studying other nonglobular flexible proteins.Entities:
Keywords: conformation analysis; immunoglobulin; ion mobility; mass spectrometry; molecular dynamics
Mesh:
Substances:
Year: 2018 PMID: 30408305 PMCID: PMC6392142 DOI: 10.1002/anie.201812018
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336
Figure 1Schematics and workflow for modelling antibody flexibility. a) Schematic representation of human IgG1–4 subclasses. b) Representative structure of IgG1, denoting hinge substructure and modes of Fab movement stemming from the upper hinge. c) Integrative workflow generating and comparing the calculated CCS values of initial, post‐sampling, and gas‐phase MD models with experimental CCS values.
Figure 2Modelling the conformational flexibility of antibodies. a) Representative mobilogram and native mass spectrum (i) and CCS distributions for 21–23+ charge states of IgG2 (ii). b) Space occupied by IgG1–4 Fabs following upper‐hinge flexibility sampling. Each sphere represents one model for each IgG Fab heavy chain (teal and purple). Light chains are shown as blue. Initial models are shown as surface representations. c) Overlay of experimental CCS distribution with triplicate simulated collapse models. Experimental error is represented by the ±6 % dotted lines. Purple error bars represent the CCS range over the last 1 ns of gas‐phase simulation.
Experimental and modelling values for IgG1–4.
| Subclass[a] | IgG1 | IgG2 | IgG3 | IgG4 |
|---|---|---|---|---|
| Theoretical mass [kDa][a] | 150 | 150 | 170 | 150 |
| Experimental mass [Da][b] | 149 328(±89) | 154 297(±42) | 162 123(±4) | 155 758(±62) |
| Experimental charge[c] | 21+ | 21+ | 22+ | 21+ |
| Overall hinge length[d] | 12 | 12 | 62 | 12 |
| No. hinge disulphides | 2 | 4 | 11 | 2 |
| Upper hinge residues sampled | 5 | 3 | 12 | 7 |
| Initial model CCS [Å2][e] | 9532 | 9747 | 10 958 | 9512 |
| Fab arm sampling CCS [Å2][f] | 8756 | 8597 | 9170 | 8484 |
| ΔCCS of sampling [Å2][g] | 1102 | 929 | 1329 | 1080 |
| Collapsed model CCS [Å2][h] | ||||
| Model 1 | 7226(±176) | 7396(±201) | 7284(±173) | 7017(±204) |
| Model 2 | 6988(±196) | 7197(±184) | 7176(±197) | 6766(±268) |
| Model 3 | 7142(±176) | 7309(±213) | 7588(±202) | 6644(±179) |
| Experimental CCS [Å2][i] | 6827(±81) | 7030(±113) | 7173(±68) | 7024(±97) |
| Deglycosylated CCS [Å2][j] | 6851(±61) | 7087(±56) | 7202(±43) | 7095(±51) |
| Net solution charge[k] | 20+ | 2− | 2+ | 2+ |
[a] Approximate mass of glycosylated protein given sequence variability in Fc and Fab regions. [b] Experimentally observed glycosylated mass from MS (± standard deviation). [c] Lowest observed experimental charge for glycosylated proteins. [d] Fc to Fab distances (Uniprot: IgG1 P01857, IgG2 P01859, IgG3 P01860, IgG4 P01861). [e] CCS=PA×1.14 calculated by IMPACT for starting models. [f] Lowest CCSmodel generated from Fab arm sampling. [g] CCSmodel range of ensemble from Fab arm sampling. [h] CCSmodel for triplicate models following 10 ns of gas‐phase simulation (± denotes CCSmodel range over final 1 ns). [i] Average CCS for lowest charge over T‐waves 550, 600, and 640 ms−1 (± standard deviation) for glycosylated proteins. [j] Average CCS for lowest charge over T‐waves 550, 600, and 640 ms−1 (± standard deviation) for deglycosylated proteins. [k] Net solution charge of each IgG molecule as determined from the Protparam webserver (Supplementary Figure 2).
Figure 3Summary of experimental and model CCS for IgG1–4. CCS was calculated for each stage of the modelling workflow. The reduction in CCS between modelling stages is shown by percentages. Error bars for the experimental data points (green) represent the standard deviation of measurement. Error bars for simulated collapse models (red) show CCS range over the last 1 ns of simulation.
Figure 4Proposed collapse pathway of IgG during ESI. a) IgG molecules exhibit full flexibility in solution. b) Nanospray ESI produces charged droplets in which IgG molecules retain partial flexibility depending on droplet size. c) Gradual evaporation of droplets coerces flexible IgG molecules into more compact topologies. Solvent charges migrate to protein surfaces as they become exposed through desolvation (CRM). d) Dry protein ions are inflexible in vacuum and represent a distribution of compact conformations.